ClinicalTrials.gg
RecruitingNCT05740709Updated Jan 23, 2024

Identification of Patients at Risk of CKD After AKI

An observational study in Acute Kidney Injury and Kidney Diseases, sponsored by Guy's and St Thomas' NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Acute Kidney Injury by Guy's and St Thomas' NHS Foundation Trust — 3 open to participants now, 5 under way, none of them phase 3. Acute Kidney Injury · Guy's and St Thomas' NHS Foundation Trust.

Started
2023
the only one that year
Observational
9 of 12
2 open now
Registered
9th of 12
by date

Among the 12 studies in Acute Kidney Injury by Guy's and St Thomas' NHS Foundation Trust, this one is the only one that started in 2023, is one of 9 observational ones, and was the 9th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

3 of the 12 studies in Acute Kidney Injury by Guy's and St Thomas' NHS Foundation Trust are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Acute Kidney Injury by Guy's and St Thomas' NHS Foundation Trust, or all of them as a file.
02

Study summary

The investigators will investigate whether new kidney biomarkers can identify patients who are at risk of chronic kidney disease after an episode of moderate / severe acute kidney injury in ICU.

Read the detailed description

Acute kidney injury (AKI) is a common complication during critical illness and associated with serious short and long-term complications. Participants with AKI have an increased risk of developing dysfunction of other organs, including multi-organ failure, a longer stay in hospital and a higher risk of dying. Survivors remain at risk of complications, even if kidney function initially recovers. In particular, they are at high risk of developing chronic kidney disease, dialysis-dependent end-stage kidney disease and cardiovascular comorbidities. At present, the tools to identify patients at highest risk of chronic kidney disease (CKD) are very limited.

The investigators will recruit participants who had AKI whilst in ICU and are scheduled to be discharged from hospital. Within 3 days of discharge from hospital, blood and urine kidney biomarkers will be measured to explore whether there is a correlation with renal function 3 months later and to identify those at highest risk of CKD. In addition, quality of life at 3 months will be assessed.

03

Conditions studied

  • Acute Kidney Injury
  • Kidney Diseases

Keywords

  • acute kidney injury
  • chronic kidney disease
  • kidney biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

critically ill adult patients in the ICU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

critically ill adult patients who had AKI stage II or III whilst in ICU and are scheduled to be discharged from hospital

Exclusion criteria

Exclusion Criteria:

  1. known pre-existing end-stage kidney disease or advanced CKD (stage 3b or worse)
  2. kidney transplant within the last 12 months
  3. known primary renal disease
  4. discharge from hospital for end-of-life care
  5. transfer to another health care institution for ongoing in-patient care
  6. not expected to survive for 3 months
  7. pregnancy
  8. lack of capacity to give consent
  9. receiving regular dialysis at hospital discharge
  10. CKD stage 3 or worse at hospital discharge
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • AKI patients

    Patients who suffered from AKI whilst in ICU and are awaiting discharge from hospital

06

What researchers measure

Primary outcomes

  1. serum creatinine

    estimated glomerular filtration rate (eGFR) \<60ml/min

    Time frame: 3 months after discharge from hospital

Secondary outcomes

  1. mortality

    mortality

    Time frame: 90 days

  2. cardiovascular morbidity

    new or worsened cardiovascular morbidity

    Time frame: 3 months post hospitalisation

  3. questionnaire

    health-related quality of life based on questionnaire EQ-5D-5L

    Time frame: 3 months post hospitalisation

07

Study locations

1 of 1 sites recruiting
  • Guy's & St Thomas Foundation Hospital
    London, SE1 7EH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jan 2025, 22 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 22 months is close to that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2022
First posted
Feb 23, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2026
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05740709
Responsible party
Sponsor
First posted
Feb 23, 2023
Start date
Mar 1, 2023
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Jan 23, 2024

Study contacts

Marlies Ostermann, PhD
Contact
Marlies.Ostermann@gstt.nhs.uk
02071887188 ext. 83035
Gill Arbane
Contact
Gill.Arbane@gstt.nhs.uk
02071887188 ext. 83035
Marlies Ostermann, PhD
principal investigator · Guy's & St Thomas' NHS Foundation Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion